Haematopoietic stem cell transplantation for refractory Takayasu's arteritis

Voltarelli, J C; Oliveira, Maria Carolina; Stracieri, Ana Beatriz Pereira Lima; Godoi, Dannielle Fernandes; Moraes, Daniela A.; Coutinho, Mário Sérgio Soares de Azeredo; Malmegrim, K. C. R.; Santos, Antônio Cardozo dos

doi:10.1093/rheumatology/keh301

Cited by 17 publications

(6 citation statements)

References 8 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All the recent studies that have relied on arteritis as Takayashu disease, reported a high efficacy success rate. The mechanisms of immunomodulation could be connected with the paracrine effects of the implanted cells [25][26][27].…”

Section: Specific Role In Inflammatory Arteritismentioning

confidence: 99%

Stem cells as a new treatment for peripheral artery disease: Hype or hope? The point of view of a vascular surgeon

Lehalle

2015

Bio-Medical Materials and Engineering

View full text Add to dashboard Cite

Because many of patients with peripheral arterial disease are not eligible for direct or conventional revascularization procedures, because stem cell therapy is being investigated as to its possible role in the treatment of limb ischemia, there is a need to evaluate this treatment and his true application. On the basis of experimental data, preliminary clinical studies have established the safety and feasibility of stem cells implantation in case of critical limb ischemia. Forthcoming large studies, especially randomized placebo controlled double blind studies, related to the optimal cell type, dosage, administration route, will consolidate this evidence and establish mid and long term effectiveness.

show abstract

Section: Specific Role In Inflammatory Arteritismentioning

confidence: 99%

Stem cells as a new treatment for peripheral artery disease: Hype or hope? The point of view of a vascular surgeon

Lehalle

2015

Bio-Medical Materials and Engineering

View full text Add to dashboard Cite

show abstract

“…Outras moléstias que apresentam resultados alvissareiros são as doenças de Chrön, polineuropatia inflamatória desmielinizante crônica, dermatomiosite/poliomiosite, poliarterite nodosa, doença de Behcet, arterite de Takayasu e diabetes mellitus tipo 1. 8,30,34,35 Em relação a esta doença, recentes relatos demonstram que a precocidade do TCTH com regime não mieloablativo propicia remissão do quadro desta doença com suspensão do uso de insulina na maioria dos pacientes (14/15) com baixa toxicidade e ausência de mortalidade relacionada ao transplante. 35 Apesar dos resultados serem promissores, existem dúvidas que ainda persistem em relação ao TCTH.…”

Section: Doenças Autoimunesunclassified

O transplante de células-tronco hematopoéticas como opção no tratamento de doenças não hematológicas

Ruiz¹,

Piron-Ruiz²,

Lago³

et al. 2009

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

show abstract

“…Some very satisfactory results were published with otherwise poor-outcome cases, such as Behçet’s vasculitic pulmonary aneurysm [61] and Behçet’s disease with intestinal involvement in a 4-year-old child [62]. Voltarelli et al [63] reported a successful transplantation in a patient with severe Takayasu arteritis. In an ongoing retrospective EBMT/EULAR study, the outcome of the currently registered patients treated with autologous transplantation for severe vasculitis will be examined.…”

Section: Hematopoietic Stem Cell Transplantation For Autoimmune Diseamentioning

confidence: 99%

Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Tyndall¹,

Daikeler²

2005

Acta Haematol

View full text Add to dashboard Cite

Ten years have passed since the first published consensus statement on the use of hematopoietic stem cell transplantation (HSCT) in the treatment of severe autoimmune disease (AD) appeared. During that time, around 700 patients suffering from severe AD have undergone HSCT in the frame of phase I/II clinical trials from over 20 countries including the US. The majority have received an autologous HSCT using one of a limited number of regimens, consistent with the original consensus statement. Long-term drug-free remissions, remission then relapse, no response and treatment-related mortality (TRM) were seen in all the subgroups of AD. An overall TRM of 7% was observed, with marked variation between ADs, i.e. 11% in systemic lupus erythematosus (SLE) and only 1 patient in rheumatoid arthritis (RA). Phase III prospective, comparative randomized trials are running or being planned in multiple sclerosis (MS), systemic sclerosis (SSc), SLE and RA. Basic science programs are also being undertaken to study the immunological mechanisms underlying the clinical events observed.

show abstract

Haematopoietic stem cell transplantation for refractory Takayasu's arteritis

Cited by 17 publications

References 8 publications

Stem cells as a new treatment for peripheral artery disease: Hype or hope? The point of view of a vascular surgeon

Stem cells as a new treatment for peripheral artery disease: Hype or hope? The point of view of a vascular surgeon

O transplante de células-tronco hematopoéticas como opção no tratamento de doenças não hematológicas

Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Contact Info

Product

Resources

About